8-Methoxyquinolones have been associated with increased bacteriostatic and bactericidal efficacy and the prevention of emergence of mutant strains in several bacteria, including Staphylococcus aureus (4, 5, 12, 23, 33) . Moxifloxacin is a new 8-methoxyquinolone with enhanced activity against gram-positive cocci, including ciprofloxacin-resistant S. aureus, with MICs 4-to 64-fold less than that of ciprofloxacin (2, 9, 15, 16, 21, 22, 30, 31) . Although single mutations in topoisomerase IV also contribute to resistance, moxifloxacin preferentially selects for gyrase mutants in Streptococcus pneumoniae (10, 14) , suggesting dual targeting of DNA gyrase and topoisomerase IV in S. pneumoniae (29, 32) . In this study, we undertook to evaluate the primary target of moxifloxacin by selection of resistant mutants as well as inhibition of the DNA supercoiling activity of DNA gyrase and the decatenation activity of topoisomerase IV. The list of strains and plasmids used in the study are shown in Table 1 .
Activity of moxifloxacin against genetically defined mutants of S. aureus. MICs of moxifloxacin and ciprofloxacin against genetically defined mutants of S. aureus determined by agar dilution on trypticase soy agar supplemented with twofoldincreasing concentrations of the antibiotics are shown in Table  2 . Moxifloxacin was four-to eightfold more active against wildtype S. aureus ISP794 than ciprofloxacin. A single gyrA mutation caused at most a twofold increase in the MICs of each quinolone, whereas a single mutation in either subunit of topoisomerase IV caused a four-to eightfold increase in MICs, suggesting topoisomerase IV to be the primary target of moxifloxacin in S. aureus. A double mutation in gyrase and topoisomerase IV caused a 125-fold increase in the MICs of both quinolones, carrying the MIC of moxifloxacin to the proposed breakpoint of resistance of Ն4 g/ml for staphylococci (1), although it remained below the achievable peak serum drug level of 4.73 g/ml with an 800-mg dose of moxifloxacin (25) . Thus, although moxifloxacin is more active than ciprofloxacin against mutants of S. aureus, it probably will not be effective against established strains with multiple resistance mutations. Overexpression of the NorA efflux pump caused at most a twofold increase in the MIC of moxifloxacin, consistent with previously published results (20) , probably due to the hydrophobicity of the 8-methoxy group as well as the bulkiness of the C-7 group (19, 27) .
Bactericidal effects of moxifloxacin and ciprofloxacin against S. aureus. The bactericidal effects of moxifloxacin and ciprofloxacin at 4 times their respective MICs were determined by performance of time-kill curves as described previously against a wild-type S. aureus strain, ISP794, and its grlA and grlA gyrA mutants (18) . Colony counts were determined immediately before the addition of the antibiotics and hourly for 5 h. Kill curves with each drug at 4 times the MIC showed similar effects for both the wild-type strain (Fig. 1A) and grlA mutant (Fig. 1B) . The killing effect of ciprofloxacin appeared more pronounced (1-log difference) for ISP794 at the drug concentrations used (1.0 g/ml for ciprofloxacin and 0.128 g/ml for moxifloxacin), perhaps due to the internal variation of MIC results (Fig. 1A) . However, a 3-log decrease in colony counts for the grlA gyrA mutant was observed with moxifloxacin, whereas ciprofloxacin produced no killing (Fig. 1C) . The concentration used for this double mutant (16 g/ml), however, was above the achievable serum drug concentrations, and at simulated peak concentrations (3 g/ml) moxifloxacin has been reported to lack bactericidal activity against highly resistant S. aureus isolates (6) .
Frequency of selection of resistant mutants. Frequencies of a single-step mutation to resistance were determined by plating S. aureus ISP794 cells on brain heart infusion agar containing either moxifloxacin or ciprofloxacin at concentrations of 2, 4, and 8 times the MIC. The experiment was repeated three times, with plating of a maximum of 4.5 ϫ 10 11 CFU. Mutation frequencies were calculated as the ratio of the number of resistant colonies at 48 h to the number of CFU inoculated. At 2 times the MIC of each quinolone, frequencies of selection of resistant mutants were similar (Table 3) . However, at 4 times the MIC, mutants could rarely be selected with moxifloxacin, and the frequency of selection of resistant mutants was 3 orders of magnitude less than that of ciprofloxacin at 4 times the MIC. Mutants could not be selected at higher concentrations of moxifloxacin.
Characterization of single-step mutants. The MICs of moxifloxacin and ciprofloxacin increased two-to eightfold for three of the four single-step mutants studied ( Table 2 ). MICs of nalidixic acid (used to screen for gyrA mutations), novobiocin (used to screen for selected grlB or grlA mutations [8] ), and ethidium bromide (used to screen for NorA overexpression [17] )
showed at most a twofold change (data not shown). The similar increase in the MICs of moxifloxacin and ciprofloxacin suggested that a mutation in topoisomerase IV was responsible for resistance, and direct sequencing of PCR products for the entirety of grlBA and the quinolone resistance-determining regions (QRDRs) of gyrBA performed using automated ABI 3100 DNA sequencers (Tufts Core Facility, Boston, Mass.) revealed two novel mutations outside the QRDR of grlB (Glu194Gly and Arg393Ser). Although genetic experiments were not performed to prove the role of these mutations in resistance, the absence of any other mutation in the entirety of grlBA suggested that these mutations were responsible for the resistance phenotype. The third mutant had a mutation in grlA (Ala176Gly), which we have previously selected with gatifloxacin (12) . We have also previously, by allelic exchange experiments, demonstrated that another amino acid substitution at the same position in GrlA (Ala176Thr) is responsible for resistance (11) . A fourth single-step mutant (M3) with a two-to fourfold increase in the MIC of moxifloxacin and at most a twofold increase in that of ciprofloxacin did not have any mutation in the entirety of grlBA and gyrBA. The MIC of ethidium bromide was also not increased for this strain, suggesting no increase in the expression of the efflux pump NorA. Se- a The indicated mutations in grlA in single-step or serial-passage mutants resulted from the following nucleotide changes: Arg17His, CGC3CAC; Glu84Lys, GAA3AAA, Ala176Gly, GCG3GGG. The indicated mutations in grlB or gyrB in single-step or serial-passage mutants resulted from the following nucleotide changes: Glu194Gly in grlB, GAG3GGG Arg393Ser in grlB, CGT3AGT, and Ser84Leu in gyrA, TCA3TTA. on September 7, 2017 by guest http://aac.asm.org/ lection of mutants without topoisomerase mutations and without evidence of increased efflux at low selecting concentrations of moxifloxacin has also been reported for S. pneumoniae (10, 14) . Selection and characterization of serial passage mutants. Serial passage of ISP794 on brain heart infusion agar containing twofold-increasing concentrations of moxifloxacin yielded mutants with up to a 64-to 128-fold increase in the MIC (4.0 g/ml). The MICs of moxifloxacin and ciprofloxacin were increased 16-to 32-fold and 8-to 16-fold, respectively, for mutant M8, the most resistant mutant in one series, and 64-to 128-fold and 128-to 256-fold for mutant M11, the most resistant mutant in a second independent series ( Table 2 ). The MICs of nalidixic acid, novobiocin, and ethidium bromide showed at most a twofold change (data not shown). Direct sequencing of the PCR products for the QRDRs of grlBA revealed a novel mutation (Arg17His) and a commonly encountered mutation (Glu87Lys) in grlA, and sequencing of the QRDRs of gyrBA revealed a common mutation in gyrA (Ser84Leu) ( Table 2) .
Activities of moxifloxacin and ciprofloxacin against purified topoisomerase IV and gyrase. The cloning of grlA, grlB, gyrA, and gyrB into expression vectors pTrcHisA, -B, or -C, purification to Ͼ90% homogeneity, and reconstitution of histidine-tagged topoisomerase IV and DNA gyrase from wild-type S. aureus ISP794 and topoisomerase IV from the GrlA mutant (Ser80Phe) as well as the specific activities of the recombinant proteins and the assay conditions for kinetoplast (kDNA) decatenation and DNA supercoiling assays have been reported previously (13) . The drug concentrations of moxifloxacin and ciprofloxacin causing 50% inhibition of kDNA decatenation by topoisomerase IV (IC 50 ), estimated visually, were similar or twofold lower for moxifloxacin (1.25 to 2.5 g/ml and 2.5 to 5.0 g/ml, respectively) ( Table 4 ; Fig.  2A ), and the IC 50 for the GrlA mutant increased similarly for both quinolones (up to 100 to 200 g/ml and 250 g/ml, respectively) (Fig. 2B) . The drug concentration causing 50% inhibition of DNA supercoiling by DNA gyrase (IC 50 ) was two-to fourfold lower for moxifloxacin than for ciprofloxacin (2.5 to 5.0 and 10 g/ml, respectively), suggesting a higher activity of moxifloxacin (Fig. 2C) . Under the assay conditions used in this study, which were different for the two assays and possibly different from the conditions in the bacterium, inhibition of topoisomerase IV and DNA gyrase by moxifloxacin was similar, if not slightly better, for topoisomerase IV, suggesting similar targeting of both enzymes. Despite similar inhibition of topoisomerase IV and DNA gyrase by moxifloxacin and ciprofloxacin, moxifloxacin was four-to eightfold more potent against S. aureus than ciprofloxacin. This discrepancy might be due to the slightly better targeting of both topoisomerase IV (at most twofold) and DNA gyrase (two-to fourfold) by moxifloxacin in comparison to that of ciprofloxacin, as well as to moxifloxacin not being a good substrate for NorA and possibly other efflux pumps. Moxifloxacin also exerts a greater bactericidal activity against S. aureus and its mutants than ciprofloxacin and selects for resistant mutants less frequently. Previously, Takei et al. have also suggested that moxifloxacin is a dual topoisomerase targeting quinolone, based on MIC ratios for topoisomerase IV and DNA gyrase mutants and inhibition of the two target enzymes (26) . Our results of in vitro activity of moxifloxacin against reconstituted S. aureus topoisomerase IV and DNA gyrase are similar to the data of Takei et al.; however, in our genetically defined mutants, we found a higher increment in the MIC of moxifloxacin in topoisomerase IV mutants than in a gyrase mutant. This finding, together with the initial selection of topoisomerase IV, suggest that moxifloxacin, similar to other 8-methoxyquinolones, preferentially targets topoisomerase IV in vivo in S. aureus. Finally, studies with newer quinolones have made localization of target gene mutations to the QRDRs much less consistent, implying more complex interactions among topoisomerases, DNA, and quinolones. 
